Sareum Announces Collaboration with Sirtris

Sareum Holdings plc has announced that it has entered into a collaborative agreement with Sirtris Pharmaceuticals.

In this collaboration, Sareum will apply its expertise in high throughput protein expression, purification and structure determination to accelerate drug discovery research at Sirtris. 

This information is invaluable in supporting Sirtris’ scientists to develop improved therapeutics aimed at promoting patients’ natural defenses against diseases of ageing, such as metabolic and neurological disease.

In return, Sareum will receive undisclosed research fees and success milestone payments.

Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, “We are very pleased that Sirtris has selected to work with Sareum as their partner in protein structure determination.” 

“This is an additional and important collaboration that Sareum has entered into in the US, which is now our major market, and provides further evidence that Sareum is a worldwide partner of choice for structure-based drug discovery.”